Dyne Therapeutics Secures $50 Million Series A Financing to Advance Targeted Therapies for Muscular Diseases

VCBeat (WeChat Official Account: vcbeat) learned from foreign media that on April 3, U.S. local time, biopharmaceutical company Dyne Therapeutics completed a $50 million Series A financing round. The funds from this round will be used to advance the development of its FORCE™ technology for the treatment of muscle diseases.

It is reported that this round of financing was led by Atlas Venture, with participation from MPM Capital and Forbion Capital Partners. In addition, Dyne Therapeutics has expanded its board of directors, and Jason Rhodes, a partner at Atlas Venture, will join the board of Dyne Therapeutics.

Dyne Therapeutics, founded in 2018, is the first biopharmaceutical company to pioneer targeted drug therapies for patients with severe muscle diseases. Led by a specialized clinical medical team, Dyne Therapeutics is developing its FORCE™ technology, which conjugates antibodies with drugs to precisely deliver therapeutics to diseased cells, thereby targeting affected tissues.

Myotonic Dystrophy Type 1 (hereinafter referred to as DM1) is a rare genetic disorder that can lead to muscle atrophy as well as cardiac and pulmonary dysfunction. The underlying cause of DM1 is mutations in the DMPK gene. Although current experimental results suggest that DM1 can be treated with targeted drugs, such therapies are not feasible because the drugs interact with other tissues upon entering the body, thereby adversely affecting human health.

Dyne Therapeutics is developing therapies for muscle diseases, aiming to help patients restore muscle health with high precision. The company’s FORCE™ technology enables the design of therapeutic agents by conjugating antibodies with oligonucleotides. The antibodies bind to receptors associated with the DMPK gene, delivering the oligonucleotides to sites of genetic mutation in muscle tissue and facilitating their entry into muscle cells. Once inside the cells, the oligonucleotides bind to pathogenic RNA and degrade it, thereby restoring muscle health.

“我们的目标是改变患有DM1和其他严重肌肉疾病的患者的健康状况。本轮融资将支持我们开展下一阶段的研究。” Dr. Romesh Subramanian, President and Chief Executive Officer of Dyne Therapeutics, said, “Our goal is to transform the health outcomes of patients with DM1 and other serious muscle diseases. This round of financing will support us in advancing our research into the next phase.”

Jason Rhodes, a partner at Atlas Venture, stated, “We are delighted to collaborate with Dyne Therapeutics on the development of novel oligonucleotide therapies, providing patients with better treatment options.”

Atlas Venture is a leading biomedical venture capital firm dedicated to investing in early-stage biomedical startups. Atlas Venture supports young entrepreneurs in building companies and focuses on the management and development of these startups.

MPM Capital is a healthcare investment firm dedicated to investing in biopharmaceutical companies in the oncology field, supporting startups in developing advanced technologies and launching novel therapeutic drugs.

Forbion Capital Partners is a venture capital firm focused on the life sciences and healthcare sector, with offices in the Netherlands and Germany. The firm primarily invests in startups in the biopharmaceutical industry and has completed 60 investments to date. Forbion Capital Partners manages ten funds with over €1 billion in assets under management.

(Compiled by Liu Yujing)